Abstract
Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 7 October 1996 / Accepted: 13 November 1996
Rights and permissions
About this article
Cite this article
Schmidt-Wolf, G., Negrin, R. & Schmidt-Wolf, I. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74, 51–56 (1997). https://doi.org/10.1007/s002770050257
Issue Date:
DOI: https://doi.org/10.1007/s002770050257